American Heart Journal
Volume 148, Issue 3 , Pages 386-392 , September 2004

Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: The Iron (FE) and Atherosclerosis Study (FEAST)

  • Leo R. Zacharski, MD

      Affiliations

    • Department of Veterans Affairs Medical Centers, White River Junction, Vt, USA
    • Department of Medicine, Dartmouth Medical School, Lebanon, NH, USA
    • Corresponding Author InformationReprint requests: Leo R. Zacharski, MD, Research Service (151), VA Medical Center, 215 North Hartland Road, White River Junction, VT 05001, USA.
    • ,
  • Bruce K. Chow, MS

      Affiliations

    • Palo Alto SCPCC, Palo Alto, Calif, USA
    • ,
  • Paula S. Howes, MS, APRN

      Affiliations

    • Department of Veterans Affairs Medical Centers, White River Junction, Vt, USA
    • ,
  • Philip W. Lavori, PhD

      Affiliations

    • Palo Alto SCPCC, Palo Alto, Calif, USA
    • ,
  • Galina Shamayeva, MS

      Affiliations

    • Palo Alto SCPCC, Palo Alto, Calif, USA

Received 23 December 2003 ,Accepted 29 March 2004.

References 

  1. Zacharski LR, Ornstein DL, Woloshin S, et al.  Association of age, sex, and race with body iron stores in adults (analysis of NHANES III data). Am Heart J. 2000;140:98–104
  2. Sullivan JL. Iron and sex difference in heart disease risk. Lancet. 1981;1:1293–1294
  3. Zacharski LR, Chow B, Lavori PW, et al.  The iron (Fe) and atherosclerosis study (FeAST) (a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease). Am Heart J. 2000;139:337–345
  4. Salonen JT, Korpela H, Nyyssonen K, et al.  Lowering of body iron stores by bloodletting and oxidation resistance of serum lipoproteins (a randomized crossover trial in male smokers). J Int Med. 1995;237:161–168
  5. van Jaarsveld J, Pool GF. Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis. 2002;16:395–402
  6. Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors (studies in carbohydrate-intolerant patients). Ann N Y Acad Sci. 2002;967:342–351
  7. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002;122:931–939
  8. Fernandez-Real JM, Penarroja G, Castro A, et al.  Blood letting in high-ferritin type 2 diabetes. Effects on insulin sensitivity and b-cell function. Diabetes. 2002;51:1000–1004
  9. Bofill C, Joven J, Bages J, et al.  Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1994;43:614–620
  10. Guillygomarc'h A, Mendler MH, Moirand R, et al.  Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol. 2001;23:344–349
  11. Duffy SJ, Biegelsen ES, Holbrook M, et al.  Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103:2799–2804
  12. Failla M, Giannattasio C, Piperno A, et al.  Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology. 2000;1:569–573
  13. Gaenzer H, Marschang P, Sturm W, et al.  Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol. 2002;1:2189–2194
  14. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002;42:1135–1139
  15. Facchini FS, Saylor KL. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes. 2003;52:1204–1209
  16. Iwasa M, Kaito M, Ikoma J, et al.  Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. Hepatogastroenterology. 2002;49:529–531
  17. Tandon N, Thakur V, Guptan KC, et al.  Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease. Br J Nutr. 2000;83:235–239
  18. Facchini FS. Near-iron deficiency-induced remission of gouty arthritis. Rheumatology 2003;42:1550–5
  19. Valenti L. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance (Correspondence). Gastroenterology. 2003;124:867–868
  20. Hershko C. Iron chelation therapy. New York: Kluwer Academic/Plenum Publishers; 2002; p. 277
  21. Cohen AR, Galanello R, Piga A, et al.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583–1587
  22. Goldman L, Hashimoto B, Cook F, et al.  Comparative reproducibility and validity of systems for assessing cardiovascular functional class (advantages of a new specific activity scale). Circulation. 1981;64:1227–1234
  23. Hlatky MA, Boineau RE, Higgenbotham MB, et al.  A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64:651–654
  24. Charlson ME, Pompei P, Ales KL, et al.  A new method of classifying prognostic comorbidity and validation. J Chron Dis. 1987;40:373–383
  25. Adams PC, Kerlesz AE, Valberg LS. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis (implications for venesection therapy). J Clin Gastroenterol. 1993;16:207–210
  26. Kiechl S, Willeit J, Egger G, et al.  Body iron stores and the risk of carotid atherosclerosis (prospective results from the Bruneck study). Circulation. 1997;96:3300–3307
  27. Lakatos E. Sample size determination in clinical trails with time dependent rates of losses and noncompliance. Control Clin Trials. 1986;7:189–199
  28. Lakatos E. Sample size based on the logrank statistic in complex clinical trials. Biometrics. 1988;44:229–241
  29. McDaniel M, Cronenwett J. Basic data related to the natural history of intermittent claudication. Ann Vasc Surg. 1989;3:273–277
  30. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:629–633
  31. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556
  32. Lavori PW, Krause-Steinrauf H, Brophy M, et al.  Principles, organization, and operation of a DNA bank for clinical trials (a Department of Veterans Affairs cooperative study). Control Clin Trials. 2002;23:222–239
  33. Dickison V. Therapeutic phlebotomy at home. J Intravenous Nursing. 1988;11:91–96

☆ Supported by the Department of Veterans Affairs Medical Research Service.

PII: S0002-8703(04)00153-X

doi: 10.1016/j.ahj.2004.03.027

American Heart Journal
Volume 148, Issue 3 , Pages 386-392 , September 2004

Article Tools

* Image Usage & Resolution